In a bold move set to shake up the weight-loss medication market, telehealth firm Hims and Hers Health has unveiled a compounded version of the popular Wegovy pill for an introductory price of $49 per month. This offering, which harnesses the same active ingredient—semaglutide—as the original product from Danish pharmaceutical giant Novo Nordisk, undercuts the brand-name medication by approximately $100.
A Competitive Edge in Weight Management
Hims and Hers Health’s new offering comes amid soaring demand for Wegovy, which was launched in January and has rapidly gained traction among consumers in the United States. The company’s alternative not only provides a more affordable option but also allows for tailored treatment plans aimed at minimising side effects—an appealing feature for many patients.
Hims CEO Andrew Dudum expressed enthusiasm about enhancing patient choice, stating, “We’re excited to find ways to continue bringing branded treatments to the platform across specialties. More choice on the platform is the best thing for customers everywhere.”
Upon signing up for a five-month subscription, patients will see their monthly cost rise to $99 after the initial offer, contrasting with Novo Nordisk’s price of $199. For those looking for shorter commitments, a three-month plan is available for a total of $277. All payments are required upfront, making the process straightforward for users.
Market Reactions and Implications
The announcement of Hims’ cheaper version sent Novo Nordisk’s shares tumbling, with early morning trading reflecting a 6% decline. This market reaction underscores the potential threat posed by Hims’ entry into the weight-loss treatment sphere. The previous partnership between the two companies in 2025, which allowed Hims to sell the injectable form of Wegovy, ended amid accusations from Novo Nordisk that Hims had improperly marketed alternatives.
Compounding, the practice of pharmacies mixing ingredients to create drug variants, remains legal in the U.S., even as branded versions are readily available. Hims has previously faced scrutiny from the Food and Drug Administration (FDA), which cautioned the company about potentially misleading claims regarding its compounded semaglutide. Despite these challenges, Hims expanded its production facility in New Albany, Ohio, in 2025, aiming to reduce costs for its treatments.
A Growing Debate on Drug Pricing
The price pressures surrounding weight-loss medications have ignited discussions on the ethics of drug pricing and patient access. While Hims aims to democratise access to treatments, Novo Nordisk has advocated for limitations on the mass production of compounded drugs to safeguard patient safety. A spokesperson from Novo was not immediately available for comment, but the company’s stance underscores the complexities of navigating the pharmaceutical landscape.
The unfolding situation highlights the broader implications of rising healthcare costs and the quest for affordable solutions. As the weight-loss medication market evolves, the competition is likely to intensify, prompting more discussions on pricing strategies and patient care.
Why it Matters
The launch of Hims and Hers Health’s affordable Wegovy alternative represents a critical moment in the ongoing battle for accessible healthcare. As consumers seek effective weight-loss solutions, the availability of lower-cost options could significantly impact patient choices and healthcare expenses. This development not only challenges established drug manufacturers but also sets the stage for a more competitive marketplace, where affordability and patient-centric care become paramount considerations. In a world where healthcare costs often outpace inflation, innovations like this could pave the way for a more equitable approach to treatment.
